Table 1
From the following article
Commercial interest waxes for IGF-1 blockers
Randy Osborne
Nature Biotechnology 26, 719 - 720 (2008)
doi:10.1038/nbt0708-719
Table 1. IGF-1 blockers in the clinic
| Company | Product | Development stage | Indication |
|---|---|---|---|
mAb, monoclonal antibody; EGFR, epidermal growth factor receptor. | |||
aUnder license from ImmunoGen (Waltham, MA). | |||
| Pfizer (New York) | CP-751,871 (fully human IgG2 mAb against IGF-1R extracellular domain) | Phase 3 | Non–small-cell lung cancer |
| CP-751,871 with Taxol (paclitaxel) and carboplatin | Phase 2 | Non–small-cell lung cancer and Ewing's sarcoma | |
| ImClone (New York) | IMC-A12 (fully human IgG1 mAb against IGF-1R extracellular domain) | Phase 2 | Head-and-neck cancer |
| IMC-A12 in combination with gemcitabine and Tarceva (erlotinib; targets EGFR tyrosine kinase domain) | Phase 1-2 | Advanced pancreatic cancer | |
| Genmab (Copenhagen)/Roche (Basel) | R1507 (fully human mAb targeting IGF-1R extracellular domain) | Phase 2 | Recurrent or refractory sarcoma |
| Roche/Sarcoma Alliance for Research through Collaboration (Ann Arbor, Michigan) | R1507 | Phase 2 | Solid tumors, including sarcoma |
| Merck (Whitehouse Station, New Jersey)/Pierre Fabre (Paris) | MK-0646 (humanized IgG1 antibody targeting IGF-1R extracellular domain) | Phase 2 | Metastatic colon cancer |
| Amgen (Thousand Oaks, California)/Takeda Bio (Tokyo) | AMG 479 (fully human mAb targeting IGF-1R extracellular domain) combined with anti-EGFR mAb panitumumab or gemcitabine | Phase 2 | Advanced solid tumors |
| Sanofi-Aventisa (Paris) | AVE-1642 (humanized IgG1 mAb targeting IGF-1R extracellular domain) with Velcade (bortezomib) | Phase 1 | Multiple myeloma |
| AVE-1642 with Taxotere (docetaxel) | Phase 1 | Solid tumors | |
